20230908-安信国际证券-微创医疗-00853.HK-2023H1收入稳健增长_运营效率大幅改善_3页_438kb

Summary of MicroPort Medical 2023 H1 Performance

MicroPort Medical reported strong growth in 2023 first-half performance, with revenue increasing by 25% year-over-year to $48.3 billion, helping narrow the net loss from $16.3 billion (narrowed 18%). This improvement stems from higher revenue and enhanced operational efficiency, which reduced period expenses.

Key business segments showed significant progress:

• Cardiovascular Intervention: Revenue surged 424% YoY to $79.2 million, driven by product launches and market expansion in international and domestic markets.
• Orthopedics: Revenue grew 10% YoY to $1.16 billion, with overseas sales recovering after supply chain issues.
• Cardiac Rhythm Management (CRM): Domestic revenue jumped 505% YoY, bolstered by MRI-compatible devices.
• Other businesses, such as surgical robotics and emerging products, also registered strong growth, contributing to overall revenue gains.

The company provided 2023 full-year guidance, expecting 25% revenue growth, with specific targets for cardiovascular intervention, CRM, and orthopedics. Operational improvements are expected to further enhance profitability.

MicroPort Medical is recommended for attention due to its diversified product portfolio and innovation in medical devices; however, risks include product development failures, pricing pressures, competition, and market uncertainties.

Disclaimer: This report does not constitute investment advice and carries standard risks as outlined by the issuer.